rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) in real world spine surgery. A phase IV, National, multicentre, retrospective study collecting data from patient medical files in French spinal centres - 19/09/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
This is a Phase IV, national, multicentre, retrospective study to observe the real-world use of rhBMP-2 in France.
Hypothesis |
There was no statistical hypothesis, the statistical analyses were descriptive in nature.
Patients and methods |
Data was collected from patient medical files in 10 French spinal centres. Primary objectives were to understand which patients were treated with rhBMP-2, commercialised in Europe as InductOs™ and how rhBMP-2 was used during spinal fusion surgery in France between 2011 and 2012.
Results |
Four hundred patients (634 levels) treated with rhBMP-2 were included in the analysis. The most frequent primary diagnostic indication for rhBMP-2 use was degenerative disc disease (DDD; 129/400; 32.3% of patients) followed by spondylolisthesis (119/400; 29.8%), deformity (59/400; 14.8%) and pseudoarthrosis (29/400; 7.3%). The most frequently treated level was L4–L5 (33.8% of levels in 53.5% of patients); followed by L5–S1 (29.8%, 47.3%), L3–L4 (16.7%, 26.5%), and L2–L3 (7.3%, 11.5%), all other levels (less than 5% of patients). No interbody fusion device was used in 42.7% of levels. Wetted matrix of rhBMP-2 was placed in the interbody space in 58.4% of levels (370/634). The most common procedure for rhBMP-2 treatment was posterior lumbar fusion (PLF) (221/634; 34.9% of levels), followed by anterior lumbar interbody fusion (ALIF) (188/634; 29.7%), posterior lumbar interbody fusion (PLIF) (111/634; 17.5%), lateral lumbar interbody fusion (LLIF) (106/634; 16.7%), transforaminal lumbar interbody fusion (TLIF) (4/634; 0.6%) and ‘other’ (4/634; 0.6%). Thirty-one adverse events of Interest (AEI) were recorded in 27 patients. One AEI was considered related to rhBMP-2. Unplanned secondary spine interventions at index level treated with rhBMP-2 were required in 4 patients.
Discussion |
In years 2011 and 2012 when the surgeries captured in this retrospective study were done, rhBMP-2 was indicated for single level (L4–S1) anterior lumbar spine fusion as a substitute for autogenous bone graft in adults with DDD. The most common procedure for the treatment with rhBMP-2 was PLF (off-label use), followed by ALIF (on-label use). The safety findings confirm a predictable and manageable safety profile.
Level of evidence |
IV.
Le texte complet de cet article est disponible en PDF.Keywords : rh-BMP-2, InductOs, Fusion, France
Plan
Vol 105 - N° 6
P. 1157-1163 - octobre 2019 Retour au numéro
Article précédent
- Correction of adult spinal deformity with a minimally invasive fusionless bipolar construct: Preliminary results
- Stéphane Wolff, Khalil Habboubi, Amer Sebaaly, Pierre Emmanuel Moreau, Lofti Miladi, Guillaume Riouallon
- Safety and efficacy of percutaneous instrumentation combined with antibiotic treatment in spondylodiscitis
- Arnauld Lambert, Yann Philippe Charles, Yves Ntilikina, Nicolas Lefebvre, Yves Hansmann, Erik André Sauleau, Jean-Paul Steib
Bienvenue sur EM-consulte, la référence des professionnels de santé.